Adalimumab (anti-TNF-alpha), TNF-α 抑制剂

    应用:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
功能和特点
  • 宿主种属: 人(Human)
  • 种属反应性: 人(Human), 小鼠(Mouse), 恒河猴(Rhesus monkey), 食蟹猴(Cynomolgus monkey)
  • 亚型: Human IgG1
  • 偶联: Unconjugated
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
A412002-100μg
100μg 现货 Stock Image
A412002-1mg
1mg 现货 Stock Image
A412002-5mg
5mg 现货 Stock Image
A412002-10mg
10mg 期货 Stock Image

基本信息

产品名称 Adalimumab (anti-TNF-alpha), TNF-α 抑制剂
别名 阿达木单抗(抗 TNF-alpha)
英文别名 dl-N-Acetylhomocysteinethiolactone | ONO5046;LY544349;EI546 | SIVELESTAT [INN] | SIVELESTAT [MART.] | 2,2-Dimethyl-propionic acid 4-[2-(carboxymethyl-carbamoyl)-phenylsulfamoyl]-phenyl ester | P,.ALPHA.,.ALPHA.-TRIMETHYLBENZYL ALCOHOL [FHFI] | J-005486 |
规格或纯度 无载体, 重组, ExactAb™, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属 人(Human)
特异性 TNFSF2/TNFa
应用 ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性 人(Human),小鼠(Mouse),恒河猴(Rhesus monkey),食蟹猴(Cynomolgus monkey)
偶联 Unconjugated
作用类型 抑制剂
作用机制 TNF-α 抑制剂

产品属性

抗体类型 Primary antibody
克隆类型 重组抗体
Format Whole IgG
亚型 Human IgG1
轻链亚型 kappa
SDS-PAGE 145.5 kDa
纯化方法 Protein A purified
纯度 >95% (SDS-PAGE&SEC)
来源 CHO supernatant
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 见COA
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息 331731-18-1
分子类型 抗体

图片

Adalimumab (anti-TNF-alpha) (A412002) - ELISA
Immobilized Recombinant Human TNF-α Protein (rp156007) at 1.0 μg/mL can bind Golimumab (anti-TNFa) (Ab175552) with the EC₅₀ of 5.78 ng/mL.

Adalimumab (anti-TNF-alpha) (A412002) - SEC
The purity of Adalimumab (anti-TNF-alpha) (A412002) is more than 95% verified by HPLC.

关联靶点(人)

ELANE Tclin 中性粒细胞弹性蛋白酶(Neutrophil elastase) (12 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
PRTN3 Tchem 髓母细胞瘤素(Myeloblastin) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
TNF Tclin 肿瘤坏死因子(Tumor necrosis factor) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

安全和危险性(GHS)

质量标准

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到3个结果

批号(Lot Number) 证书类型 日期 货号
ZJ24F0303693 分析证书 24-03-26 A412002
ZJ24F0303692 分析证书 24-03-26 A412002
ZJ24F0303691 分析证书 24-03-26 A412002

可替换产品

参考文献

1. Kempeni J.  (1999)  Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7..  Ann Rheum Dis,  58 Suppl 1  (I70-2).  [PMID:10577977]
2. Wollheim FA.  (2002)  TNF inhibition as therapy for rheumatoid arthritis..  Expert Opin Investig Drugs,  11  (7): (947-53).  [PMID:12084005]
3. Rau R.  (2002)  Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials..  Ann Rheum Dis,  61 Suppl 2  (ii70-3).  [PMID:12379628]
4. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D et al..  (2016)  Adalimumab in Patients with Active Noninfectious Uveitis..  N Engl J Med,  375  (10): (932-43).  [PMID:27602665]
5. Kawalec P, Mikrut A, Wiśniewska N, Pilc A.  (2013)  Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis..  Arch Med Sci,  (5): (765-779).  [PMID:24273556]
6. Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, Warrington S, Boyce M.  (2017)  Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects..  Br J Clin Pharmacol,  83  (7): (1405-1415).  [PMID:28133772]
7. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G et al..  (2016)  A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis..  Int J Rheum Dis,  19  (11): (1157-1168).  [PMID:26176644]
8. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B.  (2017)  Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis..  Br J Dermatol,  177  (6): (1562-1574).  [PMID:28755394]
9. Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A.  (2018)  Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications..  Expert Opin Biol Ther,  18  (8): (921-930).  [PMID:29962245]
10. Schreiber S, Yamamoto K, Muniz R, Iwura T.  (2020)  Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab..  Pharmacol Res Perspect,  (3): (e00604).  [PMID:32500668]

溶液计算器